Research programme: ataxin2 tageting antibodies - ProMIS Neurosciences
Alternative Names: Ataxin2- ProMIS NeurosciencesLatest Information Update: 16 Dec 2021
At a glance
- Originator ProMIS Neurosciences
- Class Antibodies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Amyotrophic lateral sclerosis
Most Recent Events
- 12 Nov 2021 Early research in Amyotrophic lateral sclerosis in Canada